Drug Use Disorder, Opioid Abuse, Opioid Dependence, Opioid-Related Disorders, Opioid Use
Conditions
Keywords
Relapse
Brief summary
This project examines functional connectivity patterns associated with subsequent relapse to illicit opioids during treatment for OUD.
Interventions
DIAGNOSTIC_TESTfMRI
Participants will be performing tasks while undergoing fMRI. Tasks include Stroop task, Emotion-regulation task and an Ambiguity reward task, Drug cue task, and Cognitive behavioral therapy task. Participants are not presented with any specific stimulus.
Sponsors
Yale University
National Institute on Drug Abuse (NIDA)
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
No
Inclusion criteria
* recent initiation of methadone or buprenorphine at a clinic, program, or doctor within the past year (i.e., period of time during which treatment drop-out and risk for relapse is highest); * eligibility for MRI scanning; * ability to commit to study visits.
Exclusion criteria
* current acute psychosis, mania, or suicidal ideation with intent, as assessed during screening with the SCID-5; * current intoxication or acute withdrawal at time of study visit sufficient to prevent participation based on: behavioral observation, breathalyzer, and SOWS assessment; * severe cognitive impairment as determined via trained clinical research staff through consent process and during consent quiz or as indicated by a PROMIS Cognitive Function tscore \<30 (i.e., severe impairment) * past or present history of intellectual disability, developmental disorder, or neurological disease; * head trauma with loss of consciousness \>30 min; * organ dysfunction or any unstable or untreated medical conditions that may interfere with study participation.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Illicit opioid-use | At monthly visits for 6 months following neuroimaging | Defined as the percent days of self-reported use of illicit opioids (assessed at monthly visits for 6-months following neuroimaging), with the exception of primary type of MOUD (i.e., methadone for methadone treated individuals, buprenorphine for buprenorphine treated individuals). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| MOUD retention | up to 9 months | Percentage of visits attended out of visits expected based on electronic health record data and time line follow back. |
Countries
United States
Contacts
CONTACTMonica Holler
PRINCIPAL_INVESTIGATORSarah Yip, PhD, MSc
Yale University
Outcome results
None listed